Cargando…
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologicall...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751269/ https://www.ncbi.nlm.nih.gov/pubmed/35012690 http://dx.doi.org/10.1186/s40478-021-01308-1 |
_version_ | 1784631647624232960 |
---|---|
author | Ebrahimi, Azadeh Korshunov, Andrey Reifenberger, Guido Capper, David Felsberg, Joerg Trisolini, Elena Pollo, Bianca Calatozzolo, Chiara Prinz, Marco Staszewski, Ori Schweizer, Leonille Schittenhelm, Jens Harter, Patrick N. Paulus, Werner Thomas, Christian Kohlhof-Meinecke, Patricia Seiz-Rosenhagen, Marcel Milde, Till Casalini, Belén M. Suwala, Abigail Wefers, Annika K. Reinhardt, Annekathrin Sievers, Philipp Kramm, Christof M. Etminam, Nima Unterberg, Andreas Wick, Wolfgang Herold-Mende, Christel Sturm, Dominik Pfister, Stefan M. Sill, Martin Jones, David T. W. Schrimpf, Daniel Reuss, David E. Aldape, Ken Abdullaev, Zied Sahm, Felix von Deimling, Andreas Stichel, Damian |
author_facet | Ebrahimi, Azadeh Korshunov, Andrey Reifenberger, Guido Capper, David Felsberg, Joerg Trisolini, Elena Pollo, Bianca Calatozzolo, Chiara Prinz, Marco Staszewski, Ori Schweizer, Leonille Schittenhelm, Jens Harter, Patrick N. Paulus, Werner Thomas, Christian Kohlhof-Meinecke, Patricia Seiz-Rosenhagen, Marcel Milde, Till Casalini, Belén M. Suwala, Abigail Wefers, Annika K. Reinhardt, Annekathrin Sievers, Philipp Kramm, Christof M. Etminam, Nima Unterberg, Andreas Wick, Wolfgang Herold-Mende, Christel Sturm, Dominik Pfister, Stefan M. Sill, Martin Jones, David T. W. Schrimpf, Daniel Reuss, David E. Aldape, Ken Abdullaev, Zied Sahm, Felix von Deimling, Andreas Stichel, Damian |
author_sort | Ebrahimi, Azadeh |
collection | PubMed |
description | Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA encompassed 144 tumors all subjected to DNA methylation array analysis. Sixty-two histPXA matched to the methylation class mcPXA. These were combined with the cases that showed the mcPXA signature but had received a histopathological diagnosis other than PXA. This cohort constituted a set of 220 mcPXA. Molecular and clinical parameters were analyzed in these groups. Morphological parameters were analyzed in a subset of tumors with FFPE tissue available. HistPXA revealed considerable heterogeneity in regard to methylation classes, with methylation classes glioblastoma and ganglioglioma being the most frequent mismatches. Similarly, the mcPXA cohort contained tumors of diverse histological diagnoses, with glioblastoma constituting the most frequent mismatch. Subsequent analyses demonstrated the presence of canonical pTERT mutations to be associated with unfavorable prognosis among mcPXA. Based on these data, we consider the tumor type PXA to be histologically more varied than previously assumed. Histological approach to diagnosis will predominantly identify cases with the established archetypical morphology. DNA methylation analysis includes additional tumors in the tumor class PXA that share similar DNA methylation profile but lack the typical morphology of a PXA. DNA methylation analysis also assist in separating other tumor types with morphologic overlap to PXA. Our data suggest the presence of canonical pTERT mutations as a robust indicator for poor prognosis in methylation class PXA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01308-1. |
format | Online Article Text |
id | pubmed-8751269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87512692022-01-11 Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival Ebrahimi, Azadeh Korshunov, Andrey Reifenberger, Guido Capper, David Felsberg, Joerg Trisolini, Elena Pollo, Bianca Calatozzolo, Chiara Prinz, Marco Staszewski, Ori Schweizer, Leonille Schittenhelm, Jens Harter, Patrick N. Paulus, Werner Thomas, Christian Kohlhof-Meinecke, Patricia Seiz-Rosenhagen, Marcel Milde, Till Casalini, Belén M. Suwala, Abigail Wefers, Annika K. Reinhardt, Annekathrin Sievers, Philipp Kramm, Christof M. Etminam, Nima Unterberg, Andreas Wick, Wolfgang Herold-Mende, Christel Sturm, Dominik Pfister, Stefan M. Sill, Martin Jones, David T. W. Schrimpf, Daniel Reuss, David E. Aldape, Ken Abdullaev, Zied Sahm, Felix von Deimling, Andreas Stichel, Damian Acta Neuropathol Commun Research Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA encompassed 144 tumors all subjected to DNA methylation array analysis. Sixty-two histPXA matched to the methylation class mcPXA. These were combined with the cases that showed the mcPXA signature but had received a histopathological diagnosis other than PXA. This cohort constituted a set of 220 mcPXA. Molecular and clinical parameters were analyzed in these groups. Morphological parameters were analyzed in a subset of tumors with FFPE tissue available. HistPXA revealed considerable heterogeneity in regard to methylation classes, with methylation classes glioblastoma and ganglioglioma being the most frequent mismatches. Similarly, the mcPXA cohort contained tumors of diverse histological diagnoses, with glioblastoma constituting the most frequent mismatch. Subsequent analyses demonstrated the presence of canonical pTERT mutations to be associated with unfavorable prognosis among mcPXA. Based on these data, we consider the tumor type PXA to be histologically more varied than previously assumed. Histological approach to diagnosis will predominantly identify cases with the established archetypical morphology. DNA methylation analysis includes additional tumors in the tumor class PXA that share similar DNA methylation profile but lack the typical morphology of a PXA. DNA methylation analysis also assist in separating other tumor types with morphologic overlap to PXA. Our data suggest the presence of canonical pTERT mutations as a robust indicator for poor prognosis in methylation class PXA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01308-1. BioMed Central 2022-01-10 /pmc/articles/PMC8751269/ /pubmed/35012690 http://dx.doi.org/10.1186/s40478-021-01308-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ebrahimi, Azadeh Korshunov, Andrey Reifenberger, Guido Capper, David Felsberg, Joerg Trisolini, Elena Pollo, Bianca Calatozzolo, Chiara Prinz, Marco Staszewski, Ori Schweizer, Leonille Schittenhelm, Jens Harter, Patrick N. Paulus, Werner Thomas, Christian Kohlhof-Meinecke, Patricia Seiz-Rosenhagen, Marcel Milde, Till Casalini, Belén M. Suwala, Abigail Wefers, Annika K. Reinhardt, Annekathrin Sievers, Philipp Kramm, Christof M. Etminam, Nima Unterberg, Andreas Wick, Wolfgang Herold-Mende, Christel Sturm, Dominik Pfister, Stefan M. Sill, Martin Jones, David T. W. Schrimpf, Daniel Reuss, David E. Aldape, Ken Abdullaev, Zied Sahm, Felix von Deimling, Andreas Stichel, Damian Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival |
title | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival |
title_full | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival |
title_fullStr | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival |
title_full_unstemmed | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival |
title_short | Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival |
title_sort | pleomorphic xanthoastrocytoma is a heterogeneous entity with ptert mutations prognosticating shorter survival |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751269/ https://www.ncbi.nlm.nih.gov/pubmed/35012690 http://dx.doi.org/10.1186/s40478-021-01308-1 |
work_keys_str_mv | AT ebrahimiazadeh pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT korshunovandrey pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT reifenbergerguido pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT capperdavid pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT felsbergjoerg pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT trisolinielena pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT pollobianca pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT calatozzolochiara pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT prinzmarco pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT staszewskiori pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT schweizerleonille pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT schittenhelmjens pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT harterpatrickn pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT pauluswerner pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT thomaschristian pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT kohlhofmeineckepatricia pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT seizrosenhagenmarcel pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT mildetill pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT casalinibelenm pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT suwalaabigail pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT wefersannikak pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT reinhardtannekathrin pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT sieversphilipp pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT krammchristofm pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT etminamnima pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT unterbergandreas pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT wickwolfgang pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT heroldmendechristel pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT sturmdominik pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT pfisterstefanm pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT sillmartin pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT jonesdavidtw pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT schrimpfdaniel pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT reussdavide pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT aldapeken pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT abdullaevzied pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT sahmfelix pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT vondeimlingandreas pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival AT sticheldamian pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival |